-

Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, at 3:20 p.m. ET.

Interested parties can access the live webcast here. An archived copy of the webcast will be available on the events section of the Company’s website for approximately 90 days.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. To learn more, visit www.sprucebio.com and follow us on X, LinkedIn, Facebook and YouTube.

Contacts

Media
Carolyn Hawley
Inizio Evoke Comms
Carolyn.Hawley@inizioevoke.com
media@sprucebio.com

Investors
Monique Kosse
Gilmartin Group
Monique@GilmartinIR.com
investors@sprucebio.com

Spruce Biosciences, Inc.

NASDAQ:SPRB

Release Versions

Contacts

Media
Carolyn Hawley
Inizio Evoke Comms
Carolyn.Hawley@inizioevoke.com
media@sprucebio.com

Investors
Monique Kosse
Gilmartin Group
Monique@GilmartinIR.com
investors@sprucebio.com

More News From Spruce Biosciences, Inc.

Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2025 and provided corporate updates. “2025 was a very productive year, and our team continues to execute and drive towards key milestones with our tralesinidase alfa enzyme replacement t...

Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Dale Hooks as Chief Commercial Officer. Mr. Hooks joins the company with nearly 35 years of pharmaceutical marketing and sales experience, including commercial leadership roles for 21 new product launches. Mr. Hooks...

Spruce Biosciences to Present at Upcoming Investor Conferences in March

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at two upcoming investor conferences taking place in March. Leerink Global Healthcare Conference Date and Time: March 9, 2026, at 11:20 a.m. ET Format: Firesid...
Back to Newsroom